Clinical trials
Esophageal Cancer clinical trials
Below are recruiting esophageal cancer clinical trials, each written for real people, not researchers. We’re tracking 368 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04172753Recruiting
Online MRI-guided radiation therapy on a 1.5T machine
This trial checks whether it’s practical and safe to deliver radiation treatment using real-time MRI guidance, with the process supported online. It may help patients whose doctors recommend radiation by testing a modern way to plan and deliver treatment more precisely.
Tübingen, Baden-WurttembergAges 18 years+ - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Adelaide, South AustraliaAges 18 years+ - NCT03917043RecruitingPhase 1
Testing a new targeted drug for ALK or ROS1 lung cancers
This Phase 1 trial tests APG-2449, a new drug, in people with advanced solid tumors—especially certain lung cancers that have ALK or ROS1 gene fusions. Because it’s an early safety-and-dose study, it may help learn how well the drug works and what doses are safe.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07223424RecruitingPhase 2
Patient preference study: shot vs infusion for immunotherapy
This study compares two ways to take immunotherapy drugs (nivolumab or pembrolizumab): as a shot under the skin (subcutaneous) versus an infusion into a vein (intravenous). It looks at which method patients prefer and is for people with certain advanced cancers where these drugs are already approved.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT01416714Recruiting
Tissue sample collection during cancer surgery or biopsy
This study is collecting tissue samples from people with certain cancers while they have surgery or a biopsy. It may help researchers learn more about these cancers and improve future diagnosis and treatment.
Chicago, IllinoisAges Any age - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06500052RecruitingPhase 1
Study of BL-M17D1 for HER2-positive or low-expression digestive tract and other solid tumors
This trial tests a new drug called BL-M17D1 for people with advanced or metastatic HER2-positive or low-expression gastrointestinal cancer and other solid tumors. The goal is to see if it is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Birmingham, AlabamaAges 18 years+ - NCT05517811Recruiting
Blood test changes before and after cancer surgery
This study measures a blood test (TEG) before and after surgery to see how it changes in people with certain cancers. It may help doctors better understand recovery and risk around the time of surgery.
Aurora, ColoradoAges 18–99 - NCT06713993Recruiting
Esophageal Cancer Study: Using Noninvasive Tests to Guide Care
This study is looking for people newly diagnosed with esophageal cancer or cancer at the stomach-esophagus junction who are planning to have surgery. The goal is to see if certain noninvasive tests (like scans) can help predict how the disease will progress.
BudapestAges 18 years+ - NCT05055648RecruitingPhase 3
Proton vs photon radiation for esophageal cancer before surgery
This trial compares proton therapy and standard photon therapy given before surgery for esophageal (or stomach–esophagus) cancer. It aims to see which radiation approach works better and is safer as part of a combined treatment plan.
LeuvenAges 18 years+ - NCT05357846RecruitingPhase 3
Check whether PD-1 treatment helps esophagus cancer before surgery
This Phase 3 trial tests whether adding a PD-1 medicine (sintilimab) to standard chemo-radiation before surgery improves outcomes for locally advanced esophageal squamous cell cancer. It may help by strengthening the immune response while shrinking the tumor before an operation.
Guangzhou, GuangdongAges 18–70 - NCT06474468RecruitingPhase 1/Phase 2
Study of a new drug combo for advanced esophageal cancer
This trial tests a combination of two investigational drugs for people with advanced or metastatic esophageal squamous cell carcinoma. The goal is to see if the combination can shrink tumors or slow cancer growth.
Jinan, ShandongAges 18–70 - NCT07354295Recruiting
Using AI to predict treatment response in esophageal cancer
This trial uses a combination of imaging and clinical data to see if a computer model can predict how well your treatment will work. It aims to help doctors better understand your cancer risk and choose the best treatment plan for you.
Wuhan, Other (Non U.s.)Ages Any age - NCT04221893Recruiting
Radiation therapy for metastatic gastrointestinal cancers
This trial tests whether adding radiation therapy to your current immunotherapy can help control cancer that has spread in the digestive system. It aims to improve symptoms and possibly slow the cancer's growth.
San Francisco, CaliforniaAges 18 years+ - NCT07410676RecruitingPhase 1/Phase 2
Donor NK cells with IL-15 and pembrolizumab for advanced solid tumors
This trial tests a new type of cell therapy (natural killer cells) made from a donor, combined with low-dose IL-15 (a protein that helps these cells work) and sometimes with pembrolizumab (Keytruda), for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges Any age - NCT06084897RecruitingPhase 2
Radiotherapy for metastatic esophageal cancer responding to immunotherapy
This trial tests whether adding radiotherapy can help people with metastatic esophageal cancer that has already responded well to initial treatment with immunotherapy and chemotherapy. It may offer a way to improve outcomes for those whose cancer has not progressed after 2-4 cycles of first-line treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07561840Recruiting
Exercise Training After Stomach or Esophagus Cancer Surgery
This study tests whether a guided exercise program helps people recover better after surgery for esophageal or gastric (stomach) cancer. Researchers will track your strength, fitness, and quality of life over time.
Hirakata, OsakaAges 18 years+ - NCT06431100Recruiting
A study of TRT therapy for advanced solid tumors
This trial tests a new cell therapy called TRTs for people with advanced cancers like stomach, esophagus, cervical, breast, or lung cancer that no longer respond to standard treatments. The therapy uses your own tumor tissue or fluid to create a personalized treatment.
Zhengzhou, HenanAges 18–75 - NCT00242723Recruiting
Looking at cell changes in lung, esophagus, and chest cancers
This study collects blood, urine, and tissue samples from people with lung, esophageal, or other chest cancers to look at cell changes. It does not test a new treatment—instead, it aims to better understand these cancers through research.
Bethesda, MarylandAges 2–120 - NCT03161522RecruitingPhase 2
Chemo alone versus with radiation or surgery for limited spread
This study tests whether adding radiation or surgery to chemotherapy can improve outcomes for people whose esophageal or stomach cancer has spread to only a few places. If your cancer is “oligometastatic” (up to 3 spots), the trial helps doctors see which approach gives the best control.
Houston, TexasAges 18–79 - NCT05624099RecruitingPhase 2
Camrelizumab plus chemoradiotherapy for advanced esophageal cancer
This study tests whether adding camrelizumab (an immune treatment) to standard chemoradiotherapy can control advanced esophageal squamous cell cancer. It is meant for people who have not had any prior whole-course cancer medicines for this cancer stage.
FuzhouAges 18–75 - NCT06790797Recruiting
Predicting immunotherapy success in chest cancers
This study is for people with lung or esophageal cancer who will receive immunotherapy (drugs that help your immune system fight cancer). The researchers want to find markers in your blood and tumor that can predict how well the treatment will work.
Suzhou, JiangsuAges 18–80 - NCT03712774Recruiting
Study of how chemoradiation affects quality of life
This observational study follows people with esophageal cancer to see how their quality of life changes after chemoradiation. It does not change your treatment, but it may help doctors better understand what to expect during and after therapy.
Munich, BavariaAges 18 years+
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for esophageal cancer?
- Yes. Clin2 currently lists 368 recruiting esophageal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a esophageal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a esophageal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Non Small Cell Lung Cancer
- Esophageal Cancer (EsC)
- Gastric Cancer, Gastroesophageal Junction Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Esophageal Squamous Cell Cancer
- Gastro-esophageal Junction Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.